BioCentury | Jan 9, 2021

Targeted oncology is having a moment, again

The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...
BioCentury | Dec 4, 2020

NASDAQ IPOs near $20B raised in ‘20, as Kinnate prices deal

Two years after its launch, precision oncology company Kinnate has become at least the twenty-second preclinical biotech to go public on NASDAQ this year, building upon a record the 2020 IPO class broke...
BioCentury | Nov 20, 2020

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

Pfizer’s deal with LianBio will provide the Perceptive-backed, cross-border start-up with a commercial infrastructure in China, while giving the pharma a drug hunter and development partner led by veteran China biotech executives Bing Li and Debra...
BioCentury | Nov 14, 2020

Innovation in a hurry: China biotechs see a fast track to global stage – survey

The Chinese biopharma landscape in five years will see a majority of the money magnet companies commanding innovation, with first-in-class targets filling their pipelines and innovative biologics outpacing...
BioCentury | Nov 11, 2020
Product Development

As bemarituzumab data validate FGFR2b target in gastric cancers, Five Prime shares surge after hours

HER2-negative advanced gastric cancers may be one step closer to their first targeted therapy with positive efficacy data for Five Prime’s bemarituzumab. Shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX)...
BioCentury | Sep 30, 2020
Distillery Therapeutics

An FGF21, GLP-1 fusion protein for diabetes, obesity

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Diabetes; obesity A fusion protein comprising FGF21 and GLP-1 analogs linked by an elastin-like polypeptide could treat diabetes and obesity. In HEK cells, the fusion protein agonized the FGF21 receptor complex...
BioCentury | Sep 16, 2020

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

NIH launches Accelerating Medicines Partnership for schizophreniaNIH has partnered with FDA, non-profits and biopharmas to launch the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) initiative...
BioCentury | Sep 2, 2020

NASH therapy from Novartis adds 15th program to Boston Pharmaceuticals’ pipeline

With this week’s addition of a NASH therapy from Novartis, Boston Pharmaceuticals is well on its way to the goal set by founders Christopher Viehbacher and Robert Armstrong when they launched the in-licensing play with $600 million...
BioCentury | Aug 26, 2020

Expanded management team, precision cancer therapies draw crossovers to Kinnate’s $98M series C

The presence of half a dozen crossover investors in Kinnate’s $98 million series C round suggests an IPO could be the next financing for the precision oncology company.  If it does go public this year before...
BioCentury | Aug 11, 2020
Emerging Company Profile

Through LianBio, Perceptive forms bridge for Western pipeline into Asia

Led by Bing Li and Debra Yu, Perceptive’s LianBio has launched with the goal of speeding the entrance of new medicines into Asian markets, leading with a registration-ready cardiomyopathy candidate from MyoKardia and a Phase...
Items per page:
1 - 10 of 903